Zavegepant Intranasal Spray for Migraines

Zavegepant: First Approval

(2023) Sohita Dhillon   DRUGS

Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial

(2023) Richard B Lipton et al.   LANCET NEUROLOGY

Nasal spray (Zavegepant) for migraines: a mini-review

(2023) Muhammad Omar Larik et al.   Annals of Medicine and Surgery

Zavegepant nasal spray for the acute treatment of migraine: A Phase 2/3 double‐blind, randomized, placebo‐controlled, dose‐ranging trial

(2022) Robert Croop et al.   HEADACHE

The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice

(2021) Jessica Ailani et al.   HEADACHE

Comparison of healthcare resource utilization and costs among patients with migraine with potentially adequate and insufficient triptan response

(2020) Steven C Marcus et al.   CEPHALALGIA

Migraine remains second among the world’s causes of disability, and first among young women: findings from GBD2019

(2020) T. J. Steiner et al.   JOURNAL OF HEADACHE AND PAIN

Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015

(2017) Valery L Feigin et al.   LANCET NEUROLOGY

Discovery of (R)-N-(3-(7-methyl-1H-indazol-5-yl)-1-(4-(1-methylpiperidin-4-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxamide (BMS-742413): A potent human CGRP antagonist with superior safety profile for the treatment of migraine through intranasal delivery

(2013) Prasad V. Chaturvedula et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Effects of Switching Acute Treatment on Disability in Migraine Patients Using Triptans

(2013) Daniel Serrano et al.   HEADACHE

Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults: Table 1

(2012) S.D. Silberstein et al.   NEUROLOGY